Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
Fluorine F-18 is a radioactive isotope used as a positron-emitting tracer in PET imaging to visualize metabolic and physiological processes in patients. It is administered intravenously and enables early detection of diseases such as cancer, neurological disorders, and cardiac conditions. The drug itself has no direct pharmacological mechanism but serves as a diagnostic imaging agent.
As a decades-old diagnostic asset approaching loss of exclusivity, the brand team is likely consolidating and prioritizing operational efficiency over growth-stage expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career opportunities on Fluorine F-18 are limited by zero linked job openings and the asset's LOE-approaching lifecycle stage. Professionals on this product are typically focused on defending market share, optimizing manufacturing, and supporting transition to next-generation imaging agents rather than growth initiatives.
Worked on FLUORINE F-18 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.